Robert A. Giacobbe Email and Phone Number
Robert A. Giacobbe work email
- Valid
Robert A. Giacobbe personal email
- Valid
Robert A. Giacobbe phone numbers
Expert Research Biologist with extensive history of success in the pharmaceutical industry R&D in drug discovery and development, clinical microbiology, assay development and screening, HTS, fermentation, cell culture, HPLC, automation technology and software application, statistical design, document preparation, data/project management and supervision. Expert at integrating automation around microbiological processes to optimize research throughput and outcomes. Co-discovered (Cancidas), one of Merck's more profitable drugs for the treatment of candidiasis and aspergillosis. This discovery allowed Merck to be competitive in the global antifungal market (>700 million/year).Specialties: Susceptibility testing, kill kinetics, PAE, Kirby Bauer E-test, ELISA, cell culture-bacteria, yeasts, filamentous fungi, dermatophytes, rare molds, culture identification, biocatalysis, automation-Tecan Liquid Handlers, Gemini/Freedom-EVO software, Matrix Plate Mate Plus, Quality Control (QC) and validation of liquid handlers, miniaturized microbial high through-put screening, Waters HPLC equipment software, JMP-Design of Experiments (DOE), Clinical Laboratory Standards Institute (CLSI) guidelines, FDA reference reports,GLP and life cycle management.
-
Founder, Fermentation MicrobiologyTba- Jan 2020 - PresentDiscovery and development of secondary metabolites produced by fungi and actinomycetes for anti-infectives. -
Senior Principal Scientist, MicrobiologyLifemine Therapeutics Sep 2017 - Dec 2019Cambridge, Ma, Us -
Principal Scientist, MicrobiologyWarp Drive Bio, Inc. Jul 2016 - Sep 2017
-
Senior Scientist, MicrobiologyWarp Drive Bio, Inc. Jun 2015 - Jun 2016In vitro microbiology activities in support of discovery and development programs focused on finding novel oral/IV treatments (aminoglycosides, β-lactam/β-lactamase and polymyxin) against infections caused by resistant Gram-positive and Gram-negative bacteria. Design conditions to induce secondary metabolism of native and heterologous Streptomyces sp. Design fermentation media for screening and yield improvement for production of novel antibacterial and anticancer agents.
-
Senior Scientist, Infection Innovative Medicines, Discovery And Development MicrobiologyAstrazeneca Jan 2013 - May 2015Cambridge, Cambridgeshire, GbIn vitro microbiology activities focusing on the evaluation of novel β-lactam/β-lactamase inhibitors (avibactam-like) intended for the treatment of extended spectrum β-lactamase (ESBLs) and/or metallo-β-lactamase (MBLs) bacterial infections. Evaluated ceftaroline-avibactam, aztreonam-avibactam, ceftazidime-avibactam and novel β-lactam/β-lactamase inhibitors for activity against multi-drug resistant Gram-negative pathogens (E. coli, K. pneumoniae and P. aeruginosa) expressing ESBLs, serine-based carapenemases and MBLs. -
Scientist, Infection Innovative Medicines, Discovery And Development MicrobiologyAstrazeneca Nov 2010 - Dec 2012Cambridge, Cambridgeshire, GbIn vitro microbiology activities focusing on the evaluation of novel Gyrase, DNA ligase, penicillin binding protein inhibitors (PBPI) compounds intended for the treatment of bacterial infections. Characterized thousands of lead compounds generating MIC’s, MIC50/MIC90 and kill kinetics vs. bacterial clinical pathogens. Susceptibility studies included designing testing panels of MDR Gram-positive and fastidious Gram-negative as well as resistant panels for target classes of DNA gyrase inhibitors like AZD0914 (novel spiropyrimidinetrione). Evaluated novel antibacterial agents for treatment against Staphylococcus aureus (MRSA), Neisseria gonorrhoeae, fluoroquinolone-resistant, Streptococcus pneumoniae, Enterococcus faecalis and Haemophilus influenzae.
-
Microbiology And Automation ConsultantIndependent May 2009 - Oct 2010Evaluate and identify the biological needs and determine the project scope, install automated system hardware, design software mapping of the biological process flow, write programs, run proof-of-principal studies, write SOP's and train employees.
-
Senior Research Microbiologist, Infectious Diseases ResearchMerck Jan 2007 - Apr 2009Supervised and managed pre-clinical microbiology antifungal and antibacterial in vitro whole cell susceptibility assays. Through laboratory automation improved discovery and development throughput. Worldwide responsibilities included monitoring of (Cancidas) for antifungal resistance.
-
Research Microbiologist, Infectious Diseases ResearchMerck 2001 - 2007Initiated and designed novel integrated automated laboratory for in vitro susceptibility testing, kill kinetics, PAE's, MIC50/MIC90 and geomeans for evaluation of antifungal and antibacterial agents. Led to co-discovery of 4 antifungal Pre Clinical Candidates, increased through-put and discovery rates, improved accuracy/precision and decreased development cycle times.
-
Senior Research Microbiologist, Natural Products Drug DiscoveryMerck 1996 - 2001Managed microbial fermentation discovery and development; microbial screening and media selection in production of secondary metabolites. Developed techniques for sampling, isolation, purification, growth, preservation, fermentation, microbial biocatalysis, protoplast fusion and selection for the cultivation of natural or engineered microorganisms (filamentous fungi, yeasts, actinomycetes and eubacteria) for production of novel secondary metabolites in shake flasks and pilot plant scale. Developed biologic assays-antifungal/antibacterial and HPLC to monitor complex crude fermentation extracts to detect novel compounds.
-
Research Microbiologist, Fermentation MicrobiologyMerck 1993 - 1996Managed the production of novel secondary metabolites, strain/process improvement by mutagenesis, nutrient optimization, selected inhibitors and biosynthetic precursors using statistical experimental design (DOE).
-
Staff Microbiologist, Fermentation MicrobiologyMerck 1988 - 1993Managed fungal screening for active secondary metabolites. Co-discovered pneumocandins A0 and B0 with pneumocandin B0 became the starting compound for the synthesis of the antifungal drug Cancidas.
Robert A. Giacobbe Skills
Robert A. Giacobbe Education Details
-
Fairleigh Dickinson University-Florham CampusBiology
Frequently Asked Questions about Robert A. Giacobbe
What company does Robert A. Giacobbe work for?
Robert A. Giacobbe works for Tba-
What is Robert A. Giacobbe's role at the current company?
Robert A. Giacobbe's current role is Senior Principal Scientist at LifeMine Therapeutics.
What is Robert A. Giacobbe's email address?
Robert A. Giacobbe's email address is ra****@****aol.com
What is Robert A. Giacobbe's direct phone number?
Robert A. Giacobbe's direct phone number is +161749*****
What schools did Robert A. Giacobbe attend?
Robert A. Giacobbe attended Fairleigh Dickinson University-Florham Campus.
What skills is Robert A. Giacobbe known for?
Robert A. Giacobbe has skills like Cell Culture, In Vitro, Drug Discovery, Purification, Cell, Drug Development, Glp, Laboratory Automation, Assay Development, Molecular Biology, Clinical Development, Elisa.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial